Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Analyst consensus: Ten analysts rate Corbus a consensus "Moderate Buy" (2 sell, 6 buy, 2 strong buy) with an average 1‑year price target of $43.71; Oppenheimer lifted its target to $57 while Jefferies moved to "strong‑buy" and Weiss kept a "sell."
• Pipeline: Corbus is a clinical‑stage biopharma focused on lenabasum, which is in Phase 3 for diffuse cutaneous systemic sclerosis and Phase 2 for cystic fibrosis‑related inflammation.
• Stock and recent results: CRBP trades near $9.71 (1‑year range $5.12–$20.56) with a $172M market cap; it reported a quarterly EPS loss of ($1.25) that beat estimates by $0.53, institutional investors own ~64.6% and insiders own 4% with a recent insider sale disclosed.

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten research firms that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, six have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $43.7143.

A number of brokerages have commented on CRBP. Oppenheimer lifted their price target on Corbus Pharmaceuticals from $53.00 to $57.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 10th. Jefferies Financial Group raised Corbus Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, February 18th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Corbus Pharmaceuticals in a research report on Wednesday, January 21st.

Corbus Pharmaceuticals Stock Performance

Shares of CRBP opened at $9.71 on Wednesday. The stock has a 50-day moving average of $8.56 and a two-hundred day moving average of $10.43. Corbus Pharmaceuticals has a one year low of $5.12 and a one year high of $20.56. The stock has a market cap of $172.22 million, a P/E ratio of -1.62 and a beta of 2.78.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last issued its quarterly earnings results on Monday, March 9th. The biopharmaceutical company reported ($1.25) EPS for the quarter, topping analysts' consensus estimates of ($1.78) by $0.53. Analysts predict that Corbus Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Insider Buying and Selling

In other Corbus Pharmaceuticals news, insider Dominic Smethurst sold 3,285 shares of Corbus Pharmaceuticals stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $8.09, for a total transaction of $26,575.65. Following the completion of the sale, the insider owned 95,887 shares of the company's stock, valued at approximately $775,725.83. The trade was a 3.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 4.00% of the company's stock.

Hedge Funds Weigh In On Corbus Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Velan Capital Investment Management LP raised its stake in shares of Corbus Pharmaceuticals by 3.4% during the 3rd quarter. Velan Capital Investment Management LP now owns 61,000 shares of the biopharmaceutical company's stock valued at $772,000 after buying an additional 2,000 shares during the last quarter. Mariner LLC raised its stake in shares of Corbus Pharmaceuticals by 34.0% during the 3rd quarter. Mariner LLC now owns 20,840 shares of the biopharmaceutical company's stock valued at $264,000 after buying an additional 5,289 shares during the last quarter. Persistent Asset Partners Ltd purchased a new position in shares of Corbus Pharmaceuticals during the 4th quarter valued at about $54,000. ADAR1 Capital Management LLC purchased a new position in shares of Corbus Pharmaceuticals during the 3rd quarter valued at about $129,000. Finally, Virtu Financial LLC purchased a new position in shares of Corbus Pharmaceuticals during the 4th quarter valued at about $88,000. Hedge funds and other institutional investors own 64.64% of the company's stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company's lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body's innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.